SUMMARY A refractory duodenal ulcer was arbitrarily defined as one that had failed to heal completely after treatment with cimetidine 1 g daily for three months. Of 66 patients with refractory duodenal ulcer, healing eventually occurred in 37 patients, after treatment for an average of 7*4 months. But 28 patients did not heal despite treatment for an average of 9-4 months; and one patient defaulted. In 41 patients the daily dose of cimetidine was increased to 2 g: the ulcers in 31 patients healed. In eight patients the daily dose was increased to 3 g and healing occurred in four patients. Eighteen patients required admission on 22 occasions because of severe symptoms despite treatment. Nine patients underwent surgery but in five the results were poor. Differences in clinical and endoscopic features between refractory and non-refractory ulcer patients were small. Acid and pepsin secretion were similar and gastrin concentrations normal. Blood levels of the drug and suppression of acid secretion were both satisfactory. Identification of refractory ulcer patients at the start of treatment was therefore not possible. Refractoriness could occur at any time during the course of the disease, previous treatment with cimetidine often having resulted in rapid healing, but subsequent relapses were also usually refractory. The cause of refractoriness remains unknown and the rather poor results of surgery in this series suggests that optimal management of these patients remains to be determined.
Most duodenal ulcers heal within a month of treatment with cimetidine. Of the remainder the majority heal in another one to two months of continued treatment.' Some ulcers do not heal even after a longer period of cimetidine therapy and can be considered as being 'refractory' or resistant to standard treatment. This paper presents observations on the characteristics and the course of the first 66 such patients, encountered between 1977 and 1980.
A refractory duodenal ulcer is arbitrarily defined as one that has failed to heal fully within three months of treatment with cimetidine 1 g daily, taken as 200 mg tablets three times daily and 400 mg at bedtime. This definition derives from personal experience of 495 episodes of duodenal ulceration treated between 1978 and 1980 with cimetidine 1 g daily. The cumulative healing rate was as follows: at one month, 78%; at two months, 83%; and at three months, 93%. Healing was defined as complete disappearance of all ulcers and erosions and replacement either by a scar(s) or by mucosa, even if the mucosa still appeared inflamed.
Methods

PATIENTS
Patients with duodenal ulcer(s) or with erosion(s) or with both, proven by endoscopy, were treated with cimetidine 1 g daily. Endoscopy was repeated after one to two months to check for healing. If ulcer(s) or erosion(s) were still present, the treatment was continued and healing was reassessed by endoscopy at three months. If healing was incomplete at about six to nine months, cimetidine was doubled to 2 g, even if the patient was asymptomatic, although in some patients the increase in dose was made earlier if symptoms continued or recurred. Cimetidine was increased to 3 g in the few patients in whom the combination of the 2 g dose, high dose antacid (up to 300 ml, equivalent to about 1000 mmol, daily) and rest, usually in hospital, failed to relieve severe symptoms.
In 45 patients with refractory ulcers, basal and maximal gastric secretion were each collected for one hour, the latter after stimulation with intramuscular pentagastrin 6 ,g/kg (Peptavlon®; 711 Bardhan Imperial Chemical Industries, Alderley Park, Macclesfield, UK). Acid was measured by electrometric titration to pH 7, and pepsin assayed by a modified haemoglobin substrate colorimetric method.2 In order to assess the effect of cimetidine on acid and pepsin secretion, 30 of these 45 patients had a further gastric secretion study after taking cimetidine. They took their tablets (200 mg, 400 mg, or 600 mg if their daily dose was 1 g, 2 g, or 3 g respectively) one hour before starting basal collection. For comparison, similar studies were also performed in seven patients with non-refractory ulcer.
Blood cimetidine concentrations were measured in 37 patients. A single sample was drawn one hour after taking the tablets and the serum was frozen at -20°C. Cimetidine concentrations were later measured by high pressure liquid chromatography on Lichosorb Si-60 support using an acetonilemethanol-water-ammonia solvent ( Of the 37 patients whose ulcers were judged to have healed, in the majority this was confirmed by endoscopy. In eight patients, the assessment was made at operation. The latter patients had active lesions (proven by endoscopy) a few weeks earlier, but as at laparotomy the duodenum was not opened in every instance, healing may have been overestimated.
DOSE OF CIMETIDINE AND HEALING
The relation between the dose of cimetidine and healing is shown in Figure 1 . Only eight patients healed on the standard (1 g) dose of cimetidine; but 29 of 41 patients given higher doses (2 g and 3 g) did eventually heal.
SURGERY
Despite being on cimetidine 18 of the refractory duodenal ulcer patients had to be admitted on 22 occasions to control severe pain which either persisted after starting treatment or developed after initial improvement or after a pain free interval. On the first admission, six patients came to surgery as their pain could not be controlled. The remaining 12 patients improved and were discharged; but four of these patients had to be readmitted as their symptoms worsened, often within a few weeks. On the second admission, three of the four patients had surgery. The indication for surgery in all nine patients (seven men, two women) was intractable pain despite treatment.
At laparotomy only one patient was found to have Blood concentrations of cimetidine at one hour after taking the drug were measured in 31 patients with refractory ulcer. The therapeutic range is 0.5 to 1.5 ,ug/ml, at which levels acid secretion is inhibited to the degree required for ulcer healing. Only three patients, including one patient with a non-refractory ulcer, had blood concentrations below 0.5 gg/ml, although it is possible that the peak could have been missed. Eleven patients, including the remaining five with non-refractory ulcer, had blood concentrations within the therapeutic range. The other 23 patients with a refractory ulcer had blood cimetidine concentrations above this range.
EFFECT OF CIMETIDINE ON ACID AND PEPSIN SECRETION
The degree of acid reduction varied markedly between individuals (Fig. 2) but the mean reduction of acid secretion was as great in the resistant as in the responsive patients; and several patients who had failed to heal showed marked reduction in acid secretion. The degree of inhibition of acid secretion did not appear to be dose related, and the inhibition in the non-refractory ulcer group was not different from that in the refractory ulcer groups (Table 3 ). In contrast with the marked effect on acid output, cimetidine produced less consistent and relatively little change in pepsin secretion. Patients who had secretion studies both before and during cimetidine treatment.
Acid secretion. mmol/h: mean ± SEM.
of aggressive ulceration, such as penetration and dense adhesions, this seemed a drastic step; but in retrospect it may have been a better choice. The present study suggests that the development of refractoriness may mark a change in the natural history of duodenal ulcer disease, and in some patients indicates the onset of an increased virulence of the disorder and a worsening of the prognosis. But none of the findings in this study or in those by other investigators adequately explain why some duodenal ulcers are refractory, particularly those of patients who had previously had ulcers which responded to cimetidine in standard dosage. This emphasises our continuing lack of knowledge of factors other than acid secretion which initiate and maintain ulceration of the duodenal mucosa.
